Please visit answersincme.com/DTC860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, an expert in hematologic cancers discusses management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and the future use of CAR T-cell therapies. Upon completion of this activity, participants should be better able to: Identify the unmet therapeutic needs in the management of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL); Describe the clinical evidence of novel and emerging therapies being investigated to address unmet therapeutic needs in the management of CLL/SLL; and Outline considerations for optimizing the future use of chimeric antigen receptor (CAR) T-cell therapy in the treatment of patients with relapsed/refractory CLL/SLL.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Transcript

Related